Drug developer ValiRx Plc (LON:VAL) has confirmed its peer-reviewed article analysing the used of lead drug, VAL401, has now been published online in the European Journal of Drug Metabolism and Pharmacokinetics.
The academic work focuses on data from a phase II study, completed last year in Tbilisi, Georgia.
ValiRx said in December the report was intended to be the first in a series of results-based publications on the treatment.
VAL401 is a new formulation of the antipsychotic drug risperidone, which researchers have transformed into a potential oncology treatment.
The article can be viewed by clicking on this link here.